Farmas USA

+14% y suspendida la cotizacion en el TA35 de Tel-Aviv.

TEVA

Me cago en... quien me mandaría vender ayer. En fin, así es la cosa.

14000 despidos (25% de la plantilla total) sin contar futuros cierres de plantas y oficinas, que también están previstos.

Aquí el resumen de la medidas, que se cargan también los dividendos:

-new unified and simplified organizational structure [...] by reducing layers of management, and simplifying business structures and processes

-optimization of the generics portfolio globally, and most specifically in the United States, through price adjustments and/or product discontinuation

- restructuring of its manufacturing and supply network, including the closures or divestments of a significant number of manufacturing plants in the United States, Europe, Israel and Growth Markets

-Closures or divestments of a significant number of R&D facilities, headquarters and other office locations across all geographies

- thorough review of all R&D programs across the entire company, in generics and specialty, to prioritize core projects and terminate others immediately, while maintaining a substantial pipeline

- suspend dividends on ordinary shares

The two year restructuring plan announced today is intended to reduce Teva's total cost base by $3 billion by the end of 2019, out of an estimated cost base for 2017 of $16.1 billion [...] restructuring charge as a result of the implementation of the plan in 2018 of at least $700 million

Edito: gustará al mercado, pero apostaría a que se va a cerrar el gap sin tardar muchos días

Abierta ya la cotizacion en el TA 35, + 16 %.

 TEVA

El nuevo CEO  Schultz parece que lo tiene claro.

GILD CAR-T

• Delays in getting novel therapy put sales estimates at risk
• No Medicare coverage, one-by-one rulings by private insurers

https://www.bloomberg.com/news/articles/2017-12-14/cancer-patients-with-little-time-left-wait-for-gilead-s-new-drug

CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018

https://labiotech.eu/crispr-therapeutics-clinical-trials/

se va muy afuera de las Bandas Bollinger ... me voy a pensar el corto ...

TEVA

    TEVA

 Fuera a 18,10, ahora que haga lo quiera.